Appendix. TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes. Codes. (1) Fracture locations

Similar documents
Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year. Risk of seizures associated with Ranolazine (Ranexa)

Disclosure. Learning Objectives

Trends in Glucocorticoid-Induced Osteoporosis Management Among Seniors in Ontario,

The Epilepsy Prescriber s Guide to Antiepileptic Drugs

Osteoporosis/Fracture Prevention

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

2018 American Academy of Neurology

Osteoporosis Agents Drug Class Prior Authorization Protocol

Epilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society

Antiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Osteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011

1

Forteo (teriparatide) Prior Authorization Program Summary

Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014

A Population-Based Study of the Effectiveness of Bisphosphonates at Reducing Hip Fractures among High Risk Women

Management of Epilepsy in Primary Care and the Community. Carrie Burke, Epilepsy Specialist Nurse

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

What is Osteoporosis?

Self Report Seizure Survey Summary 2017

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

Download slides:

AED Treatment Approaches. David Spencer, MD Director, OHSU Epilepsy Center Professor, Department of Neurology

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary

Epilepsy Society Therapeutic Drug Monitoring Unit (TDM Unit) Chalfont Centre for Epilepsy Chesham Lane Chalfont St Peter Buckinghamshire, SL9 ORJ

Slide 1. Slide 2. Slide 3. Objectives. Why should we care about the elderly? Antiseizure Drugs in Elderly Patients

AACE/ACE Osteoporosis Treatment Decision Tool

Osteoporosis Clinical Guideline. Rheumatology January 2017

Updated advice for nurses who care for patients with epilepsy

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010

11/7/2018 EPILEPSY UPDATE. Dr.Ram Sankaraneni. Disclosures. Speaker bureau LivaNova

APPENDIX K Pharmacological Management

Generic Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $

2018 American Academy of Neurology

John J. Wolf, DO Family Medicine

Kristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview

Index. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.

Effective Health Care

Ernie Somerville Prince of Wales Hospital EPILEPSY

Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers

Osteoporosis/Fracture Prevention Clinical Practice Guidelines

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Summary of the risk management plan by product

Osteoporosis: A Tale of 3 Task Forces!

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Osteoporosis: A Tale of 3 Task Forces!

FRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment

With osteoporosis proven to be associated with

Dumfries and Galloway. Treatment Protocol for Osteoporosis

How to treat osteoporosis With what and for how long?

Disease-Modifying, Anti-Epileptogenic, and Neuroprotective Effects of the Ketogenic Diet: Clinical Implications

Current and Emerging Strategies for Osteoporosis

Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Osteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus

Clinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Bisphosphonates. Making intelligent drug choices

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

Epilepsy: pharmacological treatment by seizure type. Clinical audit tool. Implementing NICE guidance

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Epilepsy the Essentials

Treatment of Osteoporosis: IHFD 6 th March 2015

PROVIDER GUIDE Required information on targeted HEDIS and Part D measures

Clinician s Guide to Prevention and Treatment of Osteoporosis

Osteoporosis Management

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.

Monitoring Osteoporosis Therapy

Initial Pathway for DEXA Referral and Treatment for Fracture Risk Reduction in Postmenopausal Women and Men Age 50 or Above

New Developments in Osteoporosis: Screening, Prevention and Treatment

ESETT OUTCOMES. Investigator Kick-off Meeting Robert Silbergleit, MD

Chau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences

Guidelines for the Pharmaceutical Management of Osteoporosis in Adult WA Public Hospitals

Seizure medications An overview

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Osteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009

Pharmacy Management Drug Policy

Pathway from Fracture or Risk Factor to Treatment

Awareness, Diagnosis, and Management of Osteoporosis in Adults with Developmental Disabilities

SCORECARD Questionnaire September 2012

An Update on Osteoporosis Treatments

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010

Updates in Osteoporosis

Outline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD

Page 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis

Anticonvulsants Antiseizure

SUBSPECIALTY CERTIFICATION EXAMINATION IN EPILEPSY MEDICINE Content Blueprint (December 21, 2015)

OSTEOPOROSIS MEDICINES

Osteoporosis. Overview

FINAL REPORT TO THE FLORIDA AGENCY FOR HEALTH CARE ADMINISTRATION (AHCA) Project 19

Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Bisphosphonate treatment break

Hormones & Epilepsy 18/07/61. Hormones & Women With Epilepsy (WWE) How different are women? Estradiol = Proconvulsant. Progesterone = Anticonvulsant

Transcription:

Page 1 Appendix TABLE E-1 Study Variables and Associated ICD-9-CM, HCPCS, and CPT Codes (1) Fracture locations Vertebral fracture Codes ICD-9-CM Diagnosis codes: 733.13, 805.xx, 806.xx ICD-9-CM Procedure codes: 81.65, 81.66 HCPCS codes: S2360 CPT codes: 22305, 22310, 22318, 22319, 22520, 22521, 22523, 22524, 27200, 27202 Hip, pelvic, femoral fracture ICD-9-CM Diagnosis codes: 733.14, 733.15, 733.96, 733.97, 733.98, 808.xx, 820.xx, 821.xx ICD-9-CM Procedure codes: 79.05, 79.15, 79.25, 79.35, 79.65 CPT codes: 27193, 27194, 27215, 27216, 27217, 27218, 27220, 27222, 27226, 27227, 27228, 27230, 27232, 27235, 27236, 27238, 27240, 27244, 27245, 27246, 27248, 27254, 27267, 27268, 27269, 27500, 27501, 27502, 27503, 27506, 27507, 27508, 27509, 27510, 27511, 27513, 27514 Other nonvertebral fracture Upper-limb fracture Lower-limb fracture Upper-body fracture ICD-9-CM Diagnosis codes: 733.11, 733.12, 812.xx, 813.xx, 814.xx, 815.xx, 818.xx ICD-9-CM Procedure codes: 79.01, 79.02, 79.03, 79.11, 79.12, 79.13, 79.21, 79.22, 79.23, 79.31, 79.32, 79.33, 79.61, 79.62, 79.63 CPT codes: 23600, 23605, 23615, 23616, 23620, 23625, 23630, 23665, 23670, 23675, 23680, 24500, 24505, 24515, 24516, 24530, 24535, 24538, 24545, 24546, 24560, 24565, 24566, 24575, 24576, 24577, 24579, 24582, 24620, 24635, 24650, 24655, 24665, 24666, 24670, 24675, 24685, 25500, 25505, 25515, 25520, 25525, 25526, 25530, 25535, 25545, 25560, 25565, 25574, 25575, 25600, 25605, 25606, 25607, 25608, 25609, 25622, 25624, 25628, 25630, 25635, 25645, 25650, 25651, 25652, 25680, 25685, 26600, 26605, 26607, 26608, 26615 ICD-9-CM Diagnosis codes: 733.16, 733.93, 733.94, 822.x, 823.x, 824.x, 825.x, 827.x ICD-9-CM Procedure codes: 79.06, 79.07, 79.16, 79.17, 79.26, 79.27, 79.36, 79.37, 79.66, 79.67 CPT codes: 27520, 27524, 27530, 27532, 27535, 27536, 27538, 27540, 27750, 27752, 27756, 27758, 27759, 27760, 27762, 27766, 27767, 27768, 27769, 27780, 27781, 27784, 27786, 27788, 27792, 27808, 27810, 27814, 27816, 27818, 27822, 27823, 27824, 27825, 27826, 27827, 27828, 28400, 28405, 28406, 28415, 28420, 28430, 28435, 28436, 28445, 28450, 28455, 28456, 28465, 28470, 28475, 28476, 28485, 29850, 29851, 29855, 29856 ICD-9-CM Diagnosis codes: 807.0x-807.4x, 809.xx, 810.xx, 811.xx, 819.xx CPT codes: 21800, 21805, 21810, 21820, 21825, 23500, 23505, 23515, 23570, 23575, 23585 Unspecified nonvertebral fracture ICD-9-CM Diagnosis codes: 733.10, 733.19, 733.95, 828.x (2) Fractures with trauma codes ICD-9-CM Diagnosis codes: E800-E848, E916-E919, E928.8- E928.9, E929.0-E929.1, E953, E957-E959, E960-E979, E988- E989, E999 (3) BMD assessments CPT codes: 76499, 76977, 77078, 77080, 77081, 77083, 77085, 77086, 78350, 78351

Page 2 Medications Drug class (1) Paget disease medication prescriptions filled Oral bisphosphonates (2) Osteoporosis medication prescriptions filled Anabolics Antiresorptives Oral bisphosphonates Injectable bisphosphonates Other injectable antiresorptives Other antiresorptives (3) Concomitant medication prescriptions filled Other antiresorptives Glucocorticoids Anticonvulsant therapies Generic name (dosage, if applicable) Risedronate (30 mg) Alendronate (40 mg) Etidronate (200 or 400 mg) Pamidronate disodium (30 mg) Tiludronate (400 mg) Teriparatide Alendronate (5 mg or 10 mg daily, 35 or 70 mg weekly) Risedronate (5 mg daily, 35 mg weekly, 75 or 150 mg monthly) Ibandronate (150 mg monthly) Alendronate sodium/cholecalciferol Risedronate sodium/calcium carbonate Zoledronic acid Ibandronate sodium/isopropyl alcohol Ibandronate sodium (3 ml) Ibandronate intravenous (IV) Pamidronate sodium Denosumab Raloxifene (60 mg daily) Calcitonin (200 IU/mL daily nasally) Tamoxifen (10 or 20 mg) Triamcinolone Methylprednisolone Betamethasone Hydrocortisone Prednisone Prednisolone Budesonide Dexamethasone Cortisone Perampanel Phenytoin Mephobarbital Phenobarbital Primidone Clobazam Diazepam Lorazepam Felbamate Acetazolamide Zonisamide Topiramate Rufinamide Oxcarbazepine Eslicarbazepine Carbamazepine Divalproex sodium Valproic acid Pregabalin

Page 3 Vigabatrin Tiagabine Phenytoin Ethotoin Fosphenytoin Lacosamide Ezogabine Paramethadione Trimethadione Levetiracetam Ethosuximide Methsuximide Lamotrigine

Page 4 TABLE E-2 Propensity-Score Matched Adjusted Baseline Demographic and Clinical Characteristics of Patients Exposed and Unexposed to OP MS with 12 Months of Post-Index Continuous Medicare Enrollment (Parts A and B) in the Michigan Medicare Population* Baseline Characteristic Exposed Cohort (N = 904) Unexposed Cohort (N = 904) P Value Standardized Difference Age (yr) 74.9 ± 13.4 75.1 ± 13.0 0.775 1.3 Distribution by age group <65 yr 159 (17.6%) 159 (17.6%) 1.000 0.0 65-69 yr 100 (11.1%) 90 (10.0%) 0.443 3.6 70-74 yr 124 (13.7%) 115 (12.7%) 0.532 2.9 75-79 yr 118 (13.1%) 136 (15.0%) 0.223 5.7 80-84 yr 167 (18.5%) 187 (20.7%) 0.236 5.6 85 yr 236 (26.1%) 217 (24.0%) 0.303 4.9 Sex Female 636 (70.4%) 648 (71.7%) 0.534 2.9 Race White 845 (93.5%) 829 (91.7%) 0.151 6.8 Black 34 (3.8%) 36 (4.0%) 0.807 1.2 Other 25 (2.8%) 39 (4.3%) 0.075 8.4 Socioeconomic level Low 67 (7.4%) 76 (8.4%) 0.433 3.7 Medium 313 (34.6%) 309 (34.2%) 0.843 0.9 High 471 (52.1%) 463 (51.2%) 0.707 1.8 Missing 53 (5.9%) 56 (6.2%) 0.767 1.4 Charlson Comorbidity Index score 1.4 ± 1.8 1.6 ± 1.9 0.101 7.7 Individual comorbidities Cerebrovascular disease 15 (1.7%) 17 (1.9%) 0.721 1.7 Depression/bipolar disorders 186 (20.6%) 184 (20.4%) 0.907 0.6 Diabetes mellitus 236 (26.1%) 255 (28.2%) 0.315 4.7 Kidney diseases 106 (11.7%) 102 (11.3%) 0.768 1.4 Rheumatoid arthritis 23 (2.5%) 25 (2.8%) 0.770 1.4 Dementia 102 (11.3%) 103 (11.4%) 0.941 0.4 Cancer 65 (7.2%) 73 (8.1%) 0.479 3.3 Paget disease 0 (0.0%) 0 (0.0%) 0.0 Fracture with trauma codes ± 7 days of fracture 30 (3.3%) 31 (3.4%) 0.896 0.6 date Site of first fracture Vertebral 223 (24.7%) 243 (26.9%) 0.282 5.1 Any nonvertebral 724 (80.1%) 693 (76.7%) 0.077 8.3 Hip, pelvis, femur 334 (37.0%) 352 (38.9%) 0.383 4.1 Other nonvertebral # 423 (46.8%) 368 (40.7%) 0.009** 12.3 Physician specialty for first fracture Emergency medicine 279 (30.9%) 271 (30.0%) 0.683 1.9 Internal/family medicine/general practice 227 (25.1%) 241 (26.7%) 0.452 3.5 Nurse practitioner 6 (0.7%) 7 (0.8%) 0.781 1.3 Orthopaedics 391 (43.3%) 371 (41.0%) 0.341 4.5 Radiology 21 (2.3%) 26 (2.9%) 0.460 3.5 Rehabilitation pain 22 (2.4%) 20 (2.2%) 0.755 1.5 Endocrinology 0 (0.0%) 0 (0.0%) 0.0 Rheumatology 0 (0.0%) 0 (0.0%) 0.0 Other 204 (22.6%) 217 (24.0%) 0.469 3.4 Missing 0 (0.0%) 0 (0.0%) 0.0 Time from fracture date to index date (days) 24 ± 22 23 ± 22 0.307 4.8

Page 5 Osteoporosis-related measures Filled osteoporosis medication prescriptions 65 (7.2%) 69 (7.6%) 0.720 1.7 Anabolics 5 (0.6%) 2 (0.2%) 0.256 5.3 Antiresorptives Oral bisphosphonates 43 (4.8%) 47 (5.2%) 0.665 2.0 Injectable bisphosphonates 6 (0.7%) 6 (0.7%) 1.000 0.0 Other injectable antiresorptives 2 (0.2%) 4 (0.4%) 0.413 3.8 Other antiresorptives 11 (1.2%) 11 (1.2%) 1.000 0.0 Filled concomitant medication prescriptions 256 (28.3%) 234 (25.9%) 0.244 5.5 BMD assessments 66 (7.3%) 79 (8.7%) 0.260 5.3 Filled Paget disease medications prescriptions## 0 (0.0%) 2 (0.2%) 0.157 6.7 Index year 2010 164 (18.1%) 156 (17.3%) 0.622 2.3 2011 277 (30.6%) 282 (31.2%) 0.799 1.2 2012 226 (25.0%) 238 (26.3%) 0.518 3.0 2013 237 (26.2%) 228 (25.2%) 0.628 2.3 2014 0 (0.0%) 0 (0%) 0.0 *The values are given as the number of patients, with the percentage of the cohort in parentheses, with the exception of age, Charlson Comorbidity Index, and time from fracture date to index date, which are given as the mean and standard deviation. Testing the null hypothesis of no difference between the exposed and unexposed cohorts using t tests for means and chi-square tests for proportions. Vertebral fractures; any nonvertebral fractures; hip, pelvic, or femoral fractures; and other nonvertebral fractures were identified by ICD-9-CM and HCPCS codes listed in Table E-1. Any nonvertebral fractures included those occurring in the hip, pelvis, or femur, upper limb, lower limb, upper body, or unspecified nonvertebral sites as identified by ICD- 9-CM and HCPCS codes listed in Table E-1. #Other nonvertebral fractures included those occurring in the upper limb, lower limb, upper body, or unspecified nonvertebral sites as identified by ICD-9-CM and HCPCS codes listed in Table E-1. **Significant. Osteoporosis medications included anabolics (teriparatide); antiresorptives (oral bisphosphonates [alendronate {5 or 10 mg daily, 35 or 70 mg weekly}, alendronate sodium/cholecalciferol, risedronate {5 mg daily, 35 mg weekly, 75 or 150 mg monthly}, ibandronate {150 mg monthly}, risedronate sodium/calcium carbonate]; injectable bisphosphonates [zoledronic acid, ibandronate sodium/isopropyl alcohol, ibandronate sodium {3 ml}, ibandronate intravenous {IV}, pamidronate disodium]; other injectable antiresorptives [denosumab]; and other antiresorptives [calcitonin {200 IU/mL daily nasally}, raloxifene {60 mg daily}]). Concomitant medications included other antiresorptives, glucocorticoids, and anticonvulsants detailed in Table E-1. BMD assessments were identified by CPT codes 76499, 76977, 77078, 77080, 77081, 77083, 77085, 77086, 78350, and 78351. ##Paget disease treatments included risedronate (30 mg), alendronate (40 mg), etidronate (200 or 400 mg), pamidronate disodium (30 mg), and tiludronate (400 mg).